$2.17
+0.15 (+7.43%)
Open$2.07
Previous Close$2.02
Day High$2.21
Day Low$1.98
52W High$10.26
52W Low$5.72
Volume—
Avg Volume374.0K
Market Cap122.86M
P/E Ratio50.83
EPS$0.15
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+334.1% upside
Current
$2.17
$2.17
Target
$9.42
$9.42
$6.99
$9.42 avg
$10.52
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 132.26M | 127.36M | 112.48M |
| Net Income | 2.80M | 2.65M | 2.17M |
| Profit Margin | 2.1% | 2.1% | 1.9% |
| EBITDA | 4.42M | 4.16M | 3.31M |
| Free Cash Flow | 2.17M | 2.21M | 2.87M |
| Rev Growth | +3.8% | -1.6% | +5.6% |
| Debt/Equity | 0.63 | 0.59 | 0.72 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |